Objective-To study the potential interactions in patients with endocardial permanent pacemakers and non-thoracotomy implantable cardioverter defibrillator (ICD) systems. Design-Case series and cohort study. Setting-Tertiary referral centre. Patients-Fifteen consecutive patients with both endocardial pacemakers (12 dual chamber and three single chamber) and non-thoracotomy ICD systems. Main outcome measures-Detection inhibition of induced ventricular fibrillation; double counting; and pacemaker function after shocks. In the evaluation of detection inhibition, 124 VF inductions were analysed for detection duration compared with induced VF episodes in controls with an ICD but without a pacemaker. Results-Two patients (13%) showed detection inhibition of VF and required pacemaker system change at the time of the ICD implant. With the final lead position, despite frequent pacemaker undersensing of VF, ICD detection of VF was not inhibited during any induction, and neither initial detection nor redetection times for VF were different from controls. Double/triple counting of pacemaker artefact and evoked electrogram was noted in three patients (20%). In two, this was remedied during the implantation procedure, and in the other it was abolished when amiodarone treatment was discontinued. Pacemaker function was affected by ICD discharges in two patients, one who showed postshock atrial undersensing and loss of capture, and another whose pacemaker reverted to VVI mode. Conclusions-When careful testing is performed at implantation to detect and remedy device interactions, non-thoracotomy ICD treatment and endocardial pacemakers can be used safely in combination. (Heart 1997;78:50-55) 
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(Heart 1997;78:50-55) Keywords : non-thoracotomy cardioverter defibrillators; pacemaker malfunction; cardiac pacing Ventricular demand pacing is frequently available in newer implantable cardioverter defibrillators (ICD), permitting the treatment of both bradycardia and tachycardia by a single device. Approximately 11% of patients receiving an ICD implant for the treatment of life threatening ventricular tachyarrhythmias also require a permanent pacemaker for the treatment of serious bradyarrhythmias.1 Apart from the deleterious effects on battery depletion and device longevity caused by long term pacing from the ICD, the haemodynamic requirements for rate responsiveness and atrioventricular synchrony make combination therapy necessary in most patients with complete heart block and intact sinus node function, who usually require dual chamber (DDD) pacemakers, and frequently also benefit from rate modulated (DDDR) pacing.
Potential interactions between ICDs and permanent pacemakers have long been a concern and require detailed intraoperative test-26 ing. 6 Interactions between the two implanted arrhythmia control devices may lead to inappropriate withholding of ICD shock during ventricular fibrillation (VF) as well as to inappropriate ICD shocks during normal rhythm. Despite these serious potential interactions, the safety of combined permanent pacemaker and epicardial ICD lead systems has been reported.7
Although reports of small series of patients with both permanent pacemakers and non-thoracotomy ICD systems suggest combined implantation is safe and effective, no systematic study has quantitatively addressed the issue of detection times in this population compared with a control group.8-'0 We therefore studied the interactions between pacemakers and ICDs in 15 patients receiving both endocardial systems at Lahey-Hitchcock Medical Center; specifically, we compared ventricular fibrillation (VF) detection times to clarify whether the presence of undersensing by the pacemaker delays the time to arrhythmia detection by the ICD.
Methods
Between May 1991 and November 1994, 181 non-thoracotomy ICD systems were implanted at the Lahey-Hitchcock Medical Center.
Fifteen patients (11 men) with a mean age of 67 years received an endocardial permanent pacemaker either before (nine patients) or after (six) the non-thoracotomy ICD implant, and these patients are the subject of the study. Indications for ICD implantation in these 15 patients were as follows: nine (60%) had monomorphic ventricular tachycardia (VT); four (27%) had both monomorphic VT and VF; one had sustained polymorphic VT; and one patient had VF alone. All patients were sur-50 group.bmj.com on January 28, 2018 -Published by http://heart.bmj.com/ Downloaded from Combined use of non-thoracotomy cardioverter defibrdlators and endocardial pacemakers Pacemakers were always implanted in the electrophysiology laboratory; however, two pacemaker system revisions were performed in the operating theatre at the time of ICD implantation. The pacemaker leads were also inserted preferentially through the cephalic 2-3-3-1 2-5-3-1 PPM, permanent pacemaker; IDT, initial detection time; RDT, redetection time; P2-PPM, patients with Ventak P2 and PPM; P2, patients with Ventak P2 without PPM; P-PPM, patients with Ventak P and PPM; P, patients with Ventak P without PPM. There were no significant differences (P > 0 05) between detection times in either paced or non-paced VF inductions. Double counting Double or triple counting may occur if the interval between the pacemaker stimulus (or stimuli in the case of dual chamber pacemakers) and the R wave in the bipolar ICD sensing electrogram is greater than 150 ms (refractory period of the ICD); under these circumstances both the pacemaker and the cardiac signals may be interpreted as ventricular depolarisation. If these signals occur together at a combined rate greater than the ICD tachycardia detection rate, the ICD rate detection criterion will be satisfied, a charge will be initiated, and a shock will be delivered although the underlying rhythm is neither VT nor VF.12 With the ICD programmed to the electrophysiological testing mode, double or triple counting was assessed by double or triple beeping, by means of the electrogram or event markers, depending on the ICD features. To increase the chances of double or triple counting and simulate a "worst case scenario", the permanent pacemaker was set at the maximum output and pulse width in order to magnify the size of the pacing stimulus. If no double counting was observed, the device was implanted. If double or triple counting was seen during this test the pacing lead was repositioned and the test was repeated.
Permanent pacemakerfunction after ICD discharge External and internal defibrillation has the potential to both damage pacemaker systems and reprogramme pacemaker pulse generators, usually to the "backup" mode. In addition, abnormal pacemaker sensing, as well as failure to capture, has been reported after external and endocardial shocks.6 12 All pacemakers were interrogated and a full evaluation of sensing and capture thresholds was performed after each ICD testing session in which an internal shock was delivered. All (fig 1) . Table 3 gives the data of detection times for the Ventak P and P2 compared with control groups without pacemakers. There were no differences between either initial detection or redetection times in VF episodes where pacemaker was present compared with VF episodes without pacemaker.
DOUBLE COUNTING Double counting during paced rhythm was noted in three patients (20%, fig 2) . This appeared to be sensing of the atrial pacing artefact in two, and was eliminated when the lower rate limit of the pacemaker was lowered in order to minimise atrial pacing. We have shown in this study of 15 patients undergoing combined pacemaker/ICD implantation that with careful intraoperative testing, dangerous interactions between the two devices can be revealed and remedied. Of most importance in the safety of these combined implants, we have shown that pacing during induced VF does not prevent or delay arrhythmia detection by the ICD. Our data indicate that although interactions between permanent pacemaker and ICD are common in the implantation testing of these devices, they can almost all be corrected by altering lead position and the programmed parameters of the devices. Follow up of these patients has revealed no late mortality or other complications attributable to the combined implantation, and suggests that intraoperative testing is a good index of pacemaker-ICD interaction after the patient is discharged from the hospital.
Our experience with this group of 15 patients (being a subset of 181 patients implanted with non-thoracotomy ICD alone) prompts recommendations about the management of such combined implantation procedures. Although in our series, six patients required ICD before pacemaker implants, the permanent pacemaker should if possible be implanted first and the ventricular lead placed in the right ventricular outflow tract or septum, at a distance from the rate sensing lead of the ICD, which is usually in the apex of the right ventricle (fig 4) .13 The ICD lead position in the right ventricular apex generally is optimal for defibrillation energy requirements and for lead stability, and this justifies our approach of preserving, where possible, the right apical site for the ICD lead.14 Nevertheless, clinical exigencies may preclude this strategy (fig 4 B ) and the use of an active fixation ICD lead permits the necessary implant flexibility.
Damage to the permanent pacemaker, as well as reversion to the backup mode, has been recorded following ICD shocks5; we observed one patient with this phenomenon due to an external shock before ICD implant, but none during laboratory testing and up to 48 months of follow up. This suggests that a formal evaluation of the potential for pacemaker system disruption at ICD implant is a valid index of future risk.
The ICD sensing/defibrillating lead should be placed in the right ventricular apex in order to optimise the defibrillation threshold; it should also be sited away from the permanent pacemaker lead in order to both minimise the relative amplitude of the pacing artefact seen by the ICD sensing electrode and to prevent "chatter" by electrodes making contact with each other during movement of the heart.
To prevent inappropriate ICD discharges precipitated by rapid pacing or double counting, the maximum pacing rate of the permanent pacemaker should be set at half the ICD rate detection criterion, provided that the rate of the clinical tachyarrhythmia permits this. If there is substantial crossover between physiological heart rates and the rate of the VT, then exercise testing and the use of detection enhancements such as rate stability or sudden onset criteria in the ICD is indicated; these programmed settings all require rigorous testing in the electrophysiology laboratory as well as by exercise testing before the discharge of the patient from the hospital.
The presence of bulky leads in the right and left brachiocephalic venous systems and right sided cardiac chambers might predispose patients to veno-occlusive disease and tricuspid valve regurgitation; however, this group of patients, over a relatively brief period of follow up, have experienced no such complications. Despite the previously expressed reservations of other investigators,7 we have shown that insertion of a transvenous ICD system is not precluded by the presence of a permanent endocardial pacemaker. However, the combined transvenous approach limits flexibility regarding lead placement in the right ventricle because of the need to ensure adequate sensing of both devices. Our experience reported
